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ABSTRACT With an ongoing threat posed by circulating zoonotic strains, new strat-
egies are required to prepare for the next emergent coronavirus (CoV). Previously,
groups had targeted conserved coronavirus proteins as a strategy to generate live
attenuated vaccine strains against current and future CoVs. With this in mind, we
explored whether manipulation of CoV NSP16, a conserved 2=O methyltransferase
(MTase), could provide a broad attenuation platform against future emergent strains.
Using the severe acute respiratory syndrome-CoV mouse model, an NSP16 mutant
vaccine was evaluated for protection from heterologous challenge, efficacy in the
aging host, and potential for reversion to pathogenesis. Despite some success, con-
cerns for virulence in the aged and potential for reversion makes targeting NSP16
alone an untenable approach. However, combining a 2=O MTase mutation with a
previously described CoV fidelity mutant produced a vaccine strain capable of pro-
tection from heterologous virus challenge, efficacy in aged mice, and no evidence
for reversion. Together, the results indicate that targeting the CoV 2=O MTase in par-
allel with other conserved attenuating mutations may provide a platform strategy
for rapidly generating live attenuated coronavirus vaccines.
IMPORTANCE Emergent coronaviruses remain a significant threat to global public
health and rapid response vaccine platforms are needed to stem future outbreaks.
However, failure of many previous CoV vaccine formulations has clearly highlighted
the need to test efficacy under different conditions and especially in vulnerable pop-
ulations such as the aged and immunocompromised. This study illustrates that de-
spite success in young models, the 2=O methyltransferase mutant carries too much
risk for pathogenesis and reversion in vulnerable models to be used as a stand-
alone vaccine strategy. Importantly, the 2=O methyltransferase mutation can be
paired with other attenuating approaches to provide robust protection from heterol-
ogous challenge and in vulnerable populations. Coupled with increased safety and
reduced pathogenesis, the study highlights the potential for 2=O methyltransferase
attenuation as a major component of future live attenuated coronavirus vaccines.
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The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) at thebeginning of the 21st century signaled a new era for emergent viral disease (1).
Since then, dozens of viruses have emerged from animal populations to produce
significant outbreaks in humans and transfer of zoonotic pathogens remains a major
threat to global public health (2). A decade after SARS-CoV, infections with Middle East
respiratory syndrome coronavirus (MERS-CoV) continue with periodic reintroductions
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still occurring 6 years after its initial discovery (3). Coupled with recently discovered 
SARS- and MERS-like coronaviruses circulating in animal populations, the threat of a 
coronavirus fueled outbreak remains far from remote (4). With this in mind, strategies 
must be developed to rapidly respond to a potential CoV emergence or reemergence 
event.
While the SARS- and, to a lesser extent, the MERS-CoV outbreaks have been mostly 
contained, this limitation has been primarily due to effective public health measures 
and the delayed transmissibility of the viruses until after symptomatic disease (5). 
Standard antiviral treatments with type I interferon (IFN) or traditional nucleoside 
analogs like ribavirin have shown minimal success against either epidemic strain (6). 
While several antibodies have been designed against SARS- and MERS-CoV, their 
efficacy has been found to be strain specific and may offer minimal protection against 
heterologous or unrelated coronaviruses, especially under therapeutic conditions (4, 7). 
Other drugs, targeting conserved CoV activities, have had either marginal efficacy 
in vivo or offer only a small window for treatment during early infection (8, 9). Similar 
to other viral infections, the most effective treatment for coronaviruses is prevention via 
vaccination.
In the context of both the SARS- and the MERS-CoV outbreaks, a wealth of vaccine 
strategies have been developed and examined (10, 11). Many have utilized subunit-
based approaches; others have used virus-like particles or other vector systems to 
induce immunity. While less desirable for both commercial and safety reasons, a 
number of live attenuated strains have also been developed targeting both conserved 
CoV elements or specific approaches that may be strain or group dependent (12, 13). 
For many of these vaccine approaches, protection from homologous challenge was 
noted following in vivo vaccination of young animals (10, 11). However, the failure of 
noninfectious vaccines in regard to heterologous challenge and in aged mice signaled 
a major issue in their use in vulnerable populations most impacted by coronavirus 
disease (14, 15). While some success was observed in aged mice and with heterologous 
challenge, live attenuated coronavirus vaccines have significant concerns for reversion 
and pathogenesis (16, 17). Together, the results indicate the need for an improved 
platform for coronavirus vaccines and is a major reason MERS-CoV has been included 
as a target by the Coalition for Epidemic Preparedness Innovations.
In the present study, we expand upon a live attenuated vaccine approach based on 
mutation of coronavirus NSP16, a 2=O methyltransferase (MTase). Previous work in 
murine hepatitis virus, SARS-CoV, and MERS-CoV has shown that disruption of NSP16 
activity rendered an attenuated strain sensitive to the activity of IFN-stimulated IFIT1 
(18–20). Work by our group went on to show that NSP16 mutants provided protection 
from lethal challenge by both SARS-CoV and MERS-CoV in young animals (19, 20). Here, 
we set forth to evaluate NSP16 attenuation as a platform strategy for live attenuated 
coronavirus vaccines. Using models that explore heterologous challenge, efficacy in 
aging, and potential for reversion, we found that the NSP16 mutant alone was not 
sufficiently attenuated to be used universally. However, the broad conservation of 
NSP16 coupled with robust viral yields permitted its use in combination with another 
attenuating mutation in NSP14, exonuclease (ExoN) activity. Targeting both conserved 
coronavirus activities produced a stable, attenuated virus capable of protection from 
heterologous challenge, efficacy in aged mice, and absence of reversion in immuno-
compromised models. Together, the results indicate that targeting coronavirus NSP16 
may be a critical component of a future live attenuated coronavirus vaccine approach.
RESULTS
Previous live attenuated coronavirus platforms had taken advantage of the need 
and conservation of NSP14 ExoN and the coronavirus envelope (E) proteins (16, 22). 
Similar to ExoN, the NSP16 2=O MTase has significant homology across the coronavirus 
family, more than CoV envelope proteins and the S1 portion of the CoV spike (Fig. 1A). 
Importantly, the critical KDKE enzymatic motif is highly conserved, allowing predictable
FIG 1 Host response to SARS-CoV dNSP16 CoV mirrors response to wild-type virus at early times. (A) NSP14 exonuclease (ExoN), NSP16 (2=O
MTase), envelope (E), and S1 portion of the spike (S) protein sequences of the indicated viruses were aligned, and the sequence identities were
extracted from the alignments. A heat map of the sequence identity using SARS-CoV Urbani or MERS-CoV EMC as the reference sequence was
constructed using Evolview (www.evolgenius.info/evolview). The heat map was further rendered and edited in Adobe Illustrator CC 2017. (B and
C) Twenty-week-old C57BL/6 mice mock challenged (PBS, gray) or challenged with SARS-CoV MA15 (WT, black) or SARS-CoV dNSP16 (green) at
105 PFU were examined for weight loss (n  5 for WT and dNSP16 groups) (B) and lung viral titer (C) (n  5 per group). (D) PCA analysis of total
RNA expression at individual times for WT (blue), dNSP16 (green), and mock (black) groups. Numbers (1, 2, 4, and 7) indicate the time point of
the sample. (E) Differentially expressed genes relative to the mock group were used to generate clustered expression heat maps comparing
expression in WT and dNSP16 following in vivo infection across the time course. P values were determined using a Student t test *, P  0.05; ***,
P  0.001.
disruption of the 2=O MTase function (23). As such, the NSP16 mutant viruses have 
targeted the aspartic acid (D) for mutation in SARS-CoV (D130A), MERS-CoV (D130A), 
and MHV (D129A) (18–20). Unlike ExoN and E viral mutants (16, 24–27), dNSP16 viruses 
maintain no replication attenuation in Vero cells that lack type I IFN responses (18–20). 
However, dNSP16 mutant viruses are attenuated in vivo in the context of several
coronavirus strains, including MERS-CoV (20, 23). In addition, for both SARS- and 
MERS-CoV, the NSP16 mutant viruses induce robust protection following lethal homol-
ogous challenge in vivo (19, 20). However, despite proof of concept studies, several 
questions about the efficacy of the NSP16 vaccine remain. With the absence of 
replication attenuation, it is especially important to consider the NSP16 vaccine plat-
form in the context of the overall host response. In addition, evaluation of heterologous 
challenge, aged models of disease, and the potential for reversion represent critical 
factors that must be examined prior to further pursuit as a live attenuated vaccine 
platform.
Early host response to SARS-CoV NSP16 mutant equivalent to wild-type infec-
tion. Unlike the ExoN and E protein mutants, dNSP16 coronaviruses demonstrate no 
significant attenuation in terms of viral replication in vitro except in the context of type 
I IFN pretreatment (19). Similarly, in vivo characterizations found no deficit in viral 
replication at early times (days 1 and 2) but a marked attenuation at late times 
postinfection (19, 20). These results suggest that the early portions of dNSP16 infection 
are equivalent to wild-type (WT) virus infection. To further explore this question, we 
utilized a systems biology approach to compare wild-type and dNSP16 mutant in 
20-week-old C57BL/6 mice. In this model, mice infected with mouse-adapted SARS-CoV 
experienced severe weight loss and failed to recover, and several succumbed to 
infection (Fig. 1B). Notably, while the SARS NSP16 mutant induces weight loss, mice 
recover from infection diverging from wild-type infection 3 days postinfection. Exam-
ining viral replication, the NSP16 mutant has no discernible attenuation at days 1 or 2 
(Fig. 1C); however, at day 4, a 100-fold reduction in replication is observed in the lungs 
of dNSP16-infected mice that corresponds with the kinetics of interferon-stimulated 
gene (ISG) expression. Importantly, the global host expression response models the 
same trend. Principal-component analysis (PCA) plots of total RNA expression showed 
that wild-type and mutant virus profiles cluster together at days 1 and 2 (Fig. 1D). At 
later times, similar to weight loss and viral replication, dNSP16 diverges from the WT, 
suggesting that only at late times do the host responses change following infection 
with the 2=O MTase mutant. Network analysis found similar results, with overlapping 
signatures at early time points (Fig. 1E). In contrast, late RNA expression demonstrated 
waning host responses consistent with reduced viral loads. In this context, the obser-
vation could be seen as a positive signal for inducing robust immune responses for 
vaccine responses. Conversely, the overlap with WT host responses may indicate a 
potential risk for inducing significant damage prior to attenuation of infection at late 
times.
NSP16 vaccine protects from heterologous challenge. With the continued circu-
lation of SARS- and MERS-like viruses in animal populations worldwide (4), vaccine 
approaches must consider exposure to and protection from related, heterologous 
coronavirus strains. Utilizing a chimeric mouse-adapted SARS-CoV strain incorporating 
the spike of SHC014-CoV (7), an antigenically distinct group 2B coronavirus circulating 
in Chinese horseshoe bat populations (Fig. 1A). We evaluated the efficacy of the 
SARS-CoV dNSP16 in protecting from a heterologous CoV spike with 88% amino acid 
conservation with the S1 portion of the SARS-CoV spike, the domain responsible for 
receptor binding. BALB/c mice were vaccinated with 105 PFU of SARS dNSP16, moni-
tored for 28 days, and subsequently challenged with the chimeric strain (SHC014-
MA15). Our results indicate that the attenuated 2=O MTase SARS-CoV mutant is capable 
of inducing robust protection from the zoonotic group 2B spike virus in terms of 
disease. Weight loss data, the viral lung titer, and the hemorrhage score indicated little 
to no disease in mice vaccinated with dNSP16 compared to mock-vaccinated mice (Fig. 
2A to C). Importantly, while not equivalent to neutralization of wild-type SARS-CoV, sera 
from dNSP16-vaccinated mice were able to effectively block the SHC014 chimeric virus, 
likely contributing to protection following vaccination (Fig. 2D). Together, the data 
indicate that a live attenuated NSP16 vaccine has sufficient capacity to protect from 
heterologous CoV challenge in young mice.
FIG 2 NSP16 vaccine protects from heterologous challenge. (A to C) Ten-week-old BALB/c mice were 
vaccinated with 105 PFU of SARS-CoV dNSP16 (blue) or mock vaccinated (PBS), monitored for 28 days, 
and subsequently challenged with 105 PFU of heterologous SARS-CoV expressing SHC014 spike (SHC014-
MA15). Mice were examined over a 4-day time course for weight loss (A), day 4 lung virus titer (B), and 
day 4 lung hemorrhage (C). (D) Plaque reduction neutralization titers of WT SARS-CoV (solid line) or 
heterologous SHC014-MA15 (hashed line) in sera of dNSP16-vaccinated mice. P values were determined 
using a Student t test (***, P  0.001).
Low-dose dNSP16 vaccination provides protection to aged mice. With high
rates of mortality, aged populations represent a vulnerable group in need of effective 
vaccines to coronaviruses (28). However, previous work has shown that SARS-CoV
vaccines have had mixed success in aged populations (14, 29). To explore the efficacy
of dNSP16 in a senescent model, we examined infection of 12-month-old BALB/c mice 
which recapitulates the age-dependent susceptibility observed in humans. Following
infection with 105 PFU of wild-type or dNSP16, the 2=O MTase mutant was equal to WT
SARS-CoV infection in terms of weight loss and lethality (Fig. 3A and B). While this dose
protected young mice from heterologous challenge, significant pathogenesis occurred
in the aged mice despite attenuation in viral replication at day 4 (Fig. 3C). Together, the 
data indicate that despite replication attenuation, the dNSP16 mutant harbors patho-
genic potential at high doses in aged mice.
While capable of inducing lethal disease, the utilized dose of the dNSP16 mutant 
represents a significant increase over the 50% lethal dose of WT SARS-CoV in aged mice
FIG 3 SARS-CoV dNSP16 infection risks virulence in aged mice. (A to C) Twelve-month-old BALB/c mice 
were challenged with 105 PFU of WT SARS-CoV MA15 (black) or dNSP16 (green) or mock challenged (PBS, 
gray) and then examined for weight loss (A), survival (B), and lung viral titer (C) over a time course. (D 
to F) Twelve-month-old BALB/c mice were challenged with 100 PFU of WT SARS-CoV MA15 (black) or 
dNSP16 (green) or mock challenged (PBS, gray) and then examined for weight loss (D), survival (E), lung 
viral titer (F), airway resistance (PenH) (G), and midtidal expiratory flow (EF50) (H) as measured by 
whole-body plethysmography (Buxco, DSI). P values were determined using a Student t test *, P  0.05; 
**, P  0.01; ***, P  0.001.
(30). Therefore, we challenged 12-month-old BALB/c mice with 100 PFU of WT or 
dNSP16 and evaluated the pathogenesis. Following low-dose challenge, dNSP16-
infected aged mice had reduced disease compared to control in terms of weight loss
and survival (Fig. 3D and E). The reduced pathogenesis corresponded to reduced viral
replication at both days 2 and 4, recapitulating in vivo attenuation previously observed
in young animals (Fig. 3F) (19). Notably, dNSP16 infection resulted in only marginal 
disease in terms of weight loss (5%) and respiratory parameters, including airway
resistance (PenH, Fig. 3G) and midtidal expiratory flow (EF50, Fig. 3H). To explore 
protection, 12-month-old mice were vaccinated with 100 PFU of dNSP16 and subse-
quently challenged 28 days later with a lethal dose of wild-type SARS-CoV MA15 (105
PFU). Both in terms of weight loss and survival (Fig. 4A and B), vaccination with dNSP16 
provided robust protection from lethal disease and pathogenesis; this protection
corresponded with the absence of detectable viral replication at both days 2 and 4 (Fig.
4C). Together, the results indicate that while the dNSP16 mutant harbors some risk of
pathogenicity at high doses, it can also provide aged mice with robust protection from 
lethal challenge.
NSP16 mutant reverts in immunocompromised model. Despite some important
caveats, the dNSP16 mutant has demonstrated efficacy as a vaccine following both
FIG 4 SARS-CoV dNSP16 vaccination protects aged mice. (A to C) Twelve-month-old BALB/c mice were 
vaccinated with 100 PFU of SARS-CoV dNSP16 or mock vaccinated (PBS), monitored for 28 days, and 
subsequently challenged with 105 PFU of WT SARS-CoV MA15. Mice were examined over a 4-day time 
course for weight loss (A), survival (B), and viral titer (C). P values were determined using a Student t test 
(*, P  0.05; **, P  0.01; ***, P  0.001).
heterologous challenge and in aged models of SARS-CoV disease. However, reversion 
and adaptation of a live attenuated strain represents a significant concern for its use in 
response to human epidemics. Previous studies with SARS-CoV wild-type and ExoN 
mutants found that mice lacking functional B and T cells (RAG/) were unable to clear 
virus, allowing continuous passage in vivo (16); these studies seek to utilize this model 
to examine dNSP16 infection for the possibility of reversion or adaptations resulting in 
virulence. Following infection with the SARS dNSP16 mutant, RAG/ mice were 
observed for disease and lungs harvested 30 days postinfection; individual lungs from 
eight mice were subsequently homogenized, clarified, and used to inoculate 10-week-
old BALB/c mice for reversion to virulence. The data demonstrated that for five of the 
eight in vivo-passaged virus samples, continuous infection resulted in restored viru-
lence, including weight loss and lethality (Fig. 5A and B). Importantly, we examined the 
input inoculum and found that the three samples that had no weight loss also had no 
detectable virus, suggesting clearance of the dNSP16 in these animals (Fig. 5C). With 
this in mind, the input virus samples were amplified on Vero cells, and the RNA 
sequence of NSP16 was examined for reversion. Surprisingly, the results found that all 
five virus-positive samples retained the two-nucleotide change producing the D130A 
mutation in NSP16 and suggested that virulence was not driven by reversion of the 
NSP16 mutation. Examination of the virus sequences revealed no coding changes 
outside the D130A mutation in NSP16 (Table 1). While noncoding changes were 
observed across all five recovered viruses, six mutations were conserved in all five 
recovered viruses in NSP3, NSP12, and NSP15; their potential functional impact remains 
unclear and require further study. Overall, the results indicate that the constructed 
dNSP16 mutant is not currently a viable vaccine candidate due to reversion to virulence 
in immunocompromised populations.
Viability of a multiple mechanism, live attenuated vaccine. With concerns for 
reversion and potential virulence, a live attenuated vaccine platform targeting only 
NSP16 activity should be limited to only dire circumstances. One possibility is to expand 
the NSP16 mutant beyond the original D130A mutations (two nucleotides) to include 
other members of the KDKE motif (23). Another possibility was to leverage the NSP16 
mutation in combination with other CoV live attenuation vaccine platforms. Unlike 
strategies that target fidelity (ExoN) and the envelope protein, coronavirus NSP16 
mutants have only minimal replication attenuation and demonstrate sensitivity to 
IFN-stimulated genes after initial infection. With this in mind, we set forth to evaluate 
a SARS-CoV mutant lacking both NSP16 activity and CoV fidelity (dNSP16/ExoN). 
Compared to the WT or the original dNSP16 mutant, the SARS dNSP16/ExoN virus had 
a replication deficit in its initial stock titers, as well as in a multistep growth curve (Fig. 
6A); however, the double mutant displayed replication equivalent to the SARS ExoN 
mutant, indicating that the inclusion of the NSP16 mutation produced no additional
replication attenuation in vitro. In vivo, the SARS dNSP16/ExoN mutant also had
significant attenuation relative to the WT control virus. We next infected 10-week-old
BALB/c mice with 104 PFU of either dNSP16/ExoN or WT SARS-CoV MA15, lowering the
dose due to the reduced titer in the viral stocks. Similar to the ExoN mutant (16), the
dNSP16/ExoN mutant produced no weight loss with significant changes compared to
WT infection as early as day 2 postinfection (Fig. 6B). Similarly, viral replication was
significantly attenuated at both days 2 and 4 (Fig. 6C). Finally, no signs of hemorrhage
were observed following infection with the double mutant (Fig. 6D). Together, the data
are consistent with the level of attenuation observed for the original SARS-CoV ExoN
mutant and suggested that the dNSP16/ExoN mutant may serve as a possible live
attenuated vaccine.
FIG 5 SARS-CoV dNSP16 can revert to virulence. (A to C) Eight RAG/ mice were infected with 105 PFU
of SARS-CoV dNSP16, monitored, and euthanized, and lung tissues were harvested after 30 days. Clarified
homogenates were then inoculated into 10-week-old BALB/c mice and individually monitored for weight
loss (A), survival (B), and input titer (C) prior to infection. Five of eight RAG/ homogenates (green)
produced significant weight loss and lethality and had detectable input titers. Three RAG/ homoge-
nates (black) had no disease and no detectable virus.
TABLE 1 Conserved mutations in dNSP16 mutant viruses recovered from immune-
deficient micea
Location Mutation Coding domain Amino acid change Synonymous or nonsynonymous
6459 A-G ORF1a nsp3 Q-Q Synonymous
14178 U-C ORF1b nsp12 L-L Synonymous
15740 U-C ORF1b nsp12 N-N Synonymous
19814 C-U ORF1b nsp15 Y-Y Synonymous
20528 A-G ORF1b nsp15 E-E Synonymous
20555 U-C ORF1b nsp15 D-D Synonymous
20977 A-C ORF1b nsp16 D-A Nonsynonymous (engineered)
20978 U-G ORF1b nsp16 D-A Nonsynonymous (engineered)
aSanger (dideoxy) sequencing analysis of complete viral genomes was completed on the five mutant virus-
positive samples from RAG/ mice after a single round of amplification on Vero cells.
FIG 6 SARS-CoV dNSP16/ExoN is a viable vaccine and protects from homologous and heterologous 
challenge. (A) Vero cells were infected at an MOI of 0.01 with WT SARS-CoV MA15 (black), dNSP16 (green), 
dExoN (gray), or dNSP16/ExoN (red). (B to D) Ten-week-old BALB/c mice were challenged with 104 PFU of 
SARS-CoV MA15 (black) or dNSP16/ExoN (red) and examined for weight loss (A), lung viral titer (B), and lung 
hemorrhage (C). (E to G) Ten-month-old BALB/c mice were vaccinated with 104 PFU of SARS-CoV dNSP16/
ExoN (red) or mock vaccinated (PBS, black), monitored for 28 days, and subsequently challenged with 105 
PFU of WT SARS-CoV MA15 (solid line) or SHC014-MA15 (dotted line). Mice were examined over a 4-day 
time course for weight loss (E), viral titer (F), and lung hemorrhage (G). (H) Plaque reduction neutralization 
titers of WT SARS-CoV MA15 (solid) or heterologous SHC014-MA15 (dotted) in sera from dNSP16/ExoN-
vaccinated mice. P values were determined using a Student t test (***, P  0.001).
With vaccination in mind, we explored the dNSP16/ExoN mutant in the context of 
homologous and heterologous SARS-CoV challenge. Young 10-week-old BALB/c mice 
were vaccinated with dNSP16/ExoN or mock vaccinated, monitored for 28 days, and 
subsequently challenged with homologous (SARS-MA15) or heterologous chimeric 
virus (SHC014-MA15). Following vaccination, both homologous and heterologous chal-
lenge induced significant weight loss in mock-vaccinated animals (Fig. 6E); in contrast, 
mice vaccinated with dNSP16/ExoN were protected. Similarly, dNSP16/ExoN vaccina-
tion resulted in complete ablation of viral titer at day 4 postinfection following both
homologous and heterologous challenge (Fig. 6F). In addition, hemorrhage scores 
indicated limited disease following vaccination with dNSP16/ExoN compared to control
(Fig. 6G). Importantly, sera from dNSP16/ExoN-vaccinated mice were capable of neu-
tralizing both WT SARS-CoV and chimeric spike virus (Fig. 6H). While not equivalent to
FIG 7 SARS-CoV dNSP16/ExoN protects aged mice and is cleared from immunocompromised mice. (A to D) Twelve-month-old BALB/c mice were
challenged with 100 PFU (solid line/closed circles) or 104 PFU (dotted lines/open circles) of WT SARS-CoV MA15 (black) or dNSP16/ExoN (red) and
examined for weight loss (A), survival (B), lung viral titer (C), and lung hemorrhage (D) over the time course. (E and F) Twelve-month-old BALB/c
mice were vaccinated with 100 PFU of SARS-CoV dNSP16/ExoN (red) or mock vaccinated (PBS, black), monitored for 28 days, and subsequently
challenged with 105 PFU of WT SARS-CoV MA15. Mice were examined over a 4-day time course for weight loss (E) and lung viral titer (F). (G and
H) Five RAG/ mice were infected with 104 PFU of SARS-CoV dNSP16/ExoN, monitored, and euthanized, and lung tissues were harvested after
30 days. Clarified homogenates were then inoculated into 10-week-old BALB/c mice and monitored for weight loss (G) and input titer (H). P values
were determined using a Student t test (*, P  0.05; **, P  0.01; ***, P  0.001).
neutralization induced by the dNSP16 mutant (Fig. 2), the results indicate that the 
double-mutant vaccine provided robust protection from both homologous and heter-
ologous challenge.
Double mutant protects aged mice from lethal disease. Having demonstrated 
efficacy in young mice and against heterologous challenge, we next explored the 
SARS-CoV dNSP16/ExoN mutant in the context of an aging host. Twelve-month-old 
BALB/c mice were challenged with 100 PFU of WT SARS-CoV (MA15) or the dNSP16/
ExoN mutant. Due to limited aged animals, we also challenged a small group (n  3) 
of aged mice with 104 PFU of only dNSP16/ExoN in the same experiment. In terms of 
both weight loss (Fig. 7A) and lethality (Fig. 7B), the 100-PFU dose of dNSP16/ExoN 
mutant was highly attenuated compared to the uniformly lethal WT infection at that 
dose. Similar to the young mouse challenge, the dNSP16/ExoN mutant had attenuated 
replication at days 2 and 4 postinfection (Fig. 7C) and no signs of hemorrhage (Fig. 7D) 
following the low dose. At the 104 dose, the dNSP16/ExoN mutant showed weight loss 
in one of the three aged animals (Fig. 7A); however, the viral titer showed no detectable 
virus at day 4 in any of the challenged mice (Fig. 7C). In addition, disease scores 
indicated no evidence of hemorrhage in the aged mice challenged with the high dose 
of dNSP16/ExoN (Fig. 7D). Together, the results indicate that dNSP16/ExoN mutant is 
highly attenuated following primary challenge of aged mice.
Importantly, mice vaccinated with the low dose of dNSP16/ExoN were completely 
protected from lethal SARS-CoV challenge. Both weight loss and survival showed 
complete protection in the vaccinated animals (Fig. 7E); in contrast, WT-infected mice 
had significant weight loss and two to three succumbed to infection by day 4. Titers in 
the lung demonstrated no viral replication in vaccinated aged mice; in contrast, the
lone surviving mock-vaccinated mouse had a significant titer within the lung (Fig. 7F). 
Together, the data demonstrated the utility and efficacy of the dNSP16/ExoN mutant as 
a live attenuated vaccine in aged models of disease.
SARS-CoV dNSP16/ExoN cleared from immunocompromised mice. Having ad-
dressed both heterologous challenge and efficacy in aged models, we next examined 
the dNSP16/ExoN mutation for reversion potential. Similar to the original dNSP16 
mutant, dNSP16/ExoN showed no significant disease in RAG/ mice during acute 
infection. After 30 days, mice were euthanized, and lung tissue was harvested, homog-
enized, clarified, and used to infect 10-week-old BALB/c mice. In contrast to dNSP16 
(Fig. 4), reinfection from lung homogenate of RAG/ mice infected with the double 
mutant failed to induce any significant disease in terms of weight loss or lethality upon 
acute infection (Fig. 7G). Examination of the input viral titer revealed the absence of 
detectable virus in all five RAG/ mice infected with the dNSP16/ExoN mutant (Fig. 
7H). The results indicate that following in vivo replication for 30 days, the dNSP16/ExoN 
mutant failed to revert to a virulent form. In addition, the results suggest that the 
double mutant could be cleared in immunocompromised mice without the need for 
traditional adaptive immunity. Together, the data argue that the dNSP16/ExoN mutant 
is unlikely to revert even in immunocompromised models and fulfills a key consider-
ation for a live attenuated coronavirus platform.
DISCUSSION
The threat of zoonotic coronaviruses stems not only from their potential for emer-
gence but also from the lack of effective strategies to combat epidemic coronavirus 
disease. While both SARS-CoV and MERS-CoV have been primarily limited through 
effective public health measures, future emergence events may not be as easily or 
quickly addressed. With this in mind, we evaluated the use of 2=O MTase mutants as a 
live attenuated vaccine platform to rapidly respond to current and future CoV strains. 
Our studies illustrated that despite success in standard young mouse models, the CoV 
NSP16 mutation alone carried significant risk for pathogenesis in aged animals and had 
the potential for reversion to virulence. However, pairing the NSP16 mutation with a 
second attenuating mutation provided a SARS-CoV vaccine capable of protecting 
against homologous and heterologous challenge, showing efficacy in aged mice, and 
with no evidence for virus reversion to virulence. Together, the study highlights the 
potential for NSP16 attenuation as a major feature of future live attenuated coronavirus 
vaccine approaches.
Similar to the ExoN and E proteins, NSP16 is conserved across the entire coronavirus 
family increasing its appeal as an attenuation target. While 2=O MTase activity impacts 
the immune response and pathogenesis, it is not explicitly required for viral replication, 
as demonstrated by the lack of in vitro attenuation. In contrast, both ExoN and E protein 
mutants have replication defects in vitro and have reduced overall yields during virus 
production. Importantly, this replication attenuation potentially contributes to the 
difficulty in recovering ExoN and severe attenuation of E protein mutants in the context 
of MERS-CoV infection. However, the absence of replication defects for NSP16 mutants 
offers both utility and risk. While capable of inducing robust immunity, even to 
heterologous challenge, the NSP16 mutant virus retains virulence in aged animals at 
high doses. Importantly, the augmented replication potentially contributes to its ability 
to revert to virulence in immunocompromised models. Together, the results suggest 
that the robust immunity induced by NSP16 mutants in young mice comes at the cost 
of higher virulence and the potential for reversion, thus limiting its use to only dire 
situations.
Given the risk associated with NSP16 mutation as a single target attenuation 
platform, we evaluated ways to increase safety without sacrificing vaccine efficacy. We 
first considered further targeting the other conserved residues within the KDKE motif, 
critical to 2=O MTase function. However, mutations of the SARS NSP16 (K46A, K130A) 
individually resulted in replication attenuation, potential compensatory mutations, and 
concerns for mutant viability when used in combination; in contrast, the original NSP16
mutation (D130A) produced equivalent replication requiring no need for compensatory 
mutations (19). In addition, despite the D130A mutation representing only a two-
nucleotide mutation (20, 23), none of the RAG/ passaged viruses that caused disease 
had reverted to the original residue. The results indicate that the SARS-CoV dNSP16 
mutant replicated sufficiently to permit adaptation at other sites and can restore 
virulence. These results contrast with similar experiments with SARS-CoV ExoN mutants 
which maintained the ExoN mutation in immunocompromised mice but failed to revert 
to virulence (16). Therefore, we instead focused on pairing the NSP16 mutant with 
another SARS-CoV attenuating mutation in ExoN. The combined double mutant had 
similar replication deficits as the singly targeted ExoN mutant but now featured both 
IFN/IFIT1- and fidelity-based attenuation as well. Infection with the dNSP16/ExoN 
mutant produced reduced disease in both young and aged mice. Yet, despite attenu-
ated viral replication and reduced disease, weight loss was still observed in one of three 
aged mice following high-dose challenge. While these results contrast with those for 
dNSP16 mutants and indicate attenuation of dNSP16/ExoN even at a high dose, future 
studies must consider NSP16 attenuation in the context of the aged host.
Importantly, the low dose of dNSP16/ExoN double-mutant vaccine provided robust 
protection for multiple disease models. Following both homologous and heterologous 
challenge, dNSP16/ExoN-vaccinated animals showed no signs of disease or viral repli-
cation. Similarly, vaccination of aged models induced protection from high-dose SARS-
CoV challenges. Notably, infection of RAG/ mice indicated no evidence for reversion 
since all five animals had cleared virus by 30 days postinfection. Together, the results 
indicate that targeting NSP16 in combination with another attenuating feature is an 
approach that can overcome several important barriers that previously limited live 
attenuated vaccine safety.
In pursuing vaccine platforms for coronaviruses, our data argue that a multiple-
mechanism, attenuation approach may be the fastest route to an effective and safe 
vaccine in the context of an outbreak. In this work, the absence of replication deficits 
permitted pairing of the NSP16 mutation with the less-fit SARS ExoN mutant; alterna-
tively, a SARS E protein mutant could also have been selected and has previously been 
shown to work in combination with another attenuating mutation in SARS NSP1 (17). 
However, the appeal of targeting NSP16 revolves around the lack of replication 
attenuation; for both the ExoN and E protein CoV platforms, replication attenuation 
limits their utility as a vaccine platform due the inability to recover mutants and/or 
reduce viral yields in MERS-CoV and SARS-CoV, respectively (16, 25–27). In contrast, 
NSP16 mutants in SARS and MERS-CoV have no replication deficit in vitro, allowing 
combination vaccine platforms that combine the 2=O MTASE mutation with other 
attenuating mutations. Similarly, complete conservation of the required KDKE motif 
offers a way to rapidly target NSP16 for mutation in future emergent strains similar to 
ExoN and the E protein. Importantly, translation of vaccine efficacy to heterologous 
challenge, vulnerable aged populations, and lack of reversion to virulence distinguish 
the NSP16 combination platform from other approaches tried to date.
With the emergence and ongoing outbreak of MERS-CoV in the Middle East, 
renewed efforts have been placed on effective vaccination approaches (13). Proof of 
efficacy against MERS-CoV has been explored for several platforms, including live 
attenuated viruses, DNA plasmids, virus-based vectors, nanoparticles, and recombinant 
protein strategies (11); some of these approaches have even advanced to phase I trials 
in humans (31). Yet, despite initial successes, a truly effective MERS-CoV vaccine must 
also consider vulnerable aging populations and the threat from heterologous chal-
lenge. Absent surveying these important factors, MERS-CoV vaccine approaches may 
bear similar failures that beset SARS-CoV vaccines developed a decade earlier (14, 15). 
Importantly, our studies indicate that a live attenuated SARS-CoV vaccine incorporating 
NSP16 and an additional attenuating mutation overcomes these issues and provides 
protection to vulnerable populations with limited risk for reversion. In pursuit of a 
platform to rapidly respond to an emerging threat, combination live attenuated 
vaccines employing NSP16 mutations may offer the safest path forward.
MATERIALS AND METHODS
Cells and viruses. Wild-type, mutant, and mouse-adapted SARS-CoVs were previously described (32, 
33), cultured on Vero 81 cells, and grown in Dulbecco modified Eagle medium or Opti-MEM (Gibco, CA) 
and 5% fetal clone serum (HyClone, South Logan, UT), along with antibiotic/antimycotic (Gibco, Carlsbad, 
CA). Growth curves in Vero cells were performed as previously described with multiple samples (n  3) 
examined at each time point (9, 32). Briefly, cells were washed with phosphate-buffered saline (PBS) and 
inoculated with virus or mock diluted in PBS for 40 min at 37°C. After inoculation, the cells were washed 
three times, and fresh media were added to signify time zero. Samples were harvested at the described 
time points. All virus cultivation was performed in a BSL3 laboratory with redundant fans in biosafety 
cabinets as described previously by our group (33, 34). All personnel wore powdered air purifying 
respirators (3M Breathe Easy) with Tyvek suits, aprons, and booties and were double gloved.
Construction of wild-type and mutant NSP16 and NSP16/ExoN viruses. Both wild-type and 
mutant viruses were derived from either SARS-CoV Urbani or the corresponding mouse-adapted (MA15) 
infectious clone as previously described (30, 34). For NSP16/ExoN mutant construction, we utilized the 
constructs previously generated for individual NSP16 (19) and NSP14 ExoN (16) mutants located on 
different fragments (D and E, respectively). Thereafter, plasmids containing wild-type and mutant 
SARS-CoV genome fragments were amplified, excised, ligated, and purified. In vitro transcription reac-
tions were then performed to synthesize full-length genomic RNA, which was transfected into Vero E6 
cells. The media from transfected cells were harvested and served as seed stocks for subsequent 
experiments. Viral mutants were confirmed by sequence analysis prior to use. Sequencing of 
recovered dNSP16 mutant viruses was performed as previously described (35). Synthetic construc-
tion of mutants of NSP16 and NSP14 were approved by the University of North Carolina Institutional 
Biosafety Committee.
RNA isolation, microarray processing, and identification of DE. RNA isolation and microarray 
processing, quality control, and normalization from whole-lung homogenate was carried out as previ-
ously described (36). Differential expression (DE) was determined by comparing virus-infected replicates 
to time-matched mock-infected replicates. Criteria for DE in determining the consensus ISG list were an 
absolute log2-fold change of 1.5 and a false discovery rate-adjusted P value of 0.05 for a given time 
point.
Clustering and functional enrichment. Genes identified as differentially expressed were used to 
generate clustered expression heat maps. Hierarchical clustering (using Euclidean distance and complete 
linkage clustering) was used to cluster gene expression according to behavior across experimental 
conditions. Mouse GO terms (www.geneontology.org) and the EASE-adjusted Fisher exact test (37) were 
used to determine functional enrichment results for the genes in each cluster. Functional enrichment 
output was manually summarized for each cluster. PCA plots and cluster diagrams were generated using 
the prcomp() function in the R base package and the gplots R package, respectively.
Ethics statement. This study was carried out in accordance with the recommendations for care and 
use of animals by the Office of Laboratory Animal Welfare, National Institutes of Health. The Institutional 
Animal Care and Use Committee (IACUC) of The University of North Carolina at Chapel Hill (UNC, permit 
A-3410-01) approved the animal study protocol (IACUC protocol 15-009 and 13-072) followed in this 
study.
Mouse infections. Mice (10 weeks old and 12 months old) were anesthetized with ketamine and 
xylazine (in accordance with IACUC/UNC guidelines) and intranasally inoculated with a 50-l volume 
containing 102 to 105 PFU of SARS-CoV MA15, SARS-CoV dNSP16, SARS-CoV dNSP16/ExoN virus, or a PBS 
mock treatment, as indicated in the figure legends. For vaccination experiments, mice were infected with 
vaccination doses of SARS-CoV dNSP16 or SARS-CoV dNSP16/ExoN as described above, monitored for 
clinical symptoms for 7 days, and then challenged 4 weeks postvaccination with 105 PFU of SARS-CoV 
MA15. Infected animals were monitored for weight loss, morbidity, and clinical signs of disease, and lung 
titers were determined as described previously (30). Young and aged female BALB/c mice were 
purchased from Envigo/Harlan Labs; female RAG/ mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME).
Virus neutralization assays. Plaque reduction neutralization titer assays were performed with 
previously characterized antibodies against SARS-CoV as previously described (38). Briefly, neutralizing 
antibodies or serum were serially diluted 2-fold and incubated with 100 PFU of the different virus strains 
for 1 h at 37°C. The virus and antibodies were then added to a 6-well plate with 5  105 Vero E6 cells/well 
with n  2. After a 1-h incubation at 37°C, cells were overlaid with 3 ml of 0.8% agarose in media. Plates 
were incubated for 2 days at 37°C and then stained with neutral red for 3 h, and the plaques were 
counted. The percentage of plaque reduction was calculated as follows: (1  [number of plaques with 
antibody/number of plaques without antibody])  100.
Accession number(s). Raw microarray data for these studies were deposited in publicly available 
databases in the National Center for Biotechnology Information’s Gene Expression Omnibus (39) under 
accession no. GSE49263.
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